PL3664787T3 - Zastosowanie selektywnych agonistów receptora serotoninowego 5-HT1A do leczenia skutków ubocznych inhibitorów VMAT - Google Patents

Zastosowanie selektywnych agonistów receptora serotoninowego 5-HT1A do leczenia skutków ubocznych inhibitorów VMAT

Info

Publication number
PL3664787T3
PL3664787T3 PL18740248.2T PL18740248T PL3664787T3 PL 3664787 T3 PL3664787 T3 PL 3664787T3 PL 18740248 T PL18740248 T PL 18740248T PL 3664787 T3 PL3664787 T3 PL 3664787T3
Authority
PL
Poland
Prior art keywords
effects
receptor agonists
selective serotonin
ht1a receptor
treating side
Prior art date
Application number
PL18740248.2T
Other languages
English (en)
Inventor
Anna Wesolowska
Magdalena JASTRZEBSKA-WIESEK
Adrian Newman-Tancredi
Mark Andrew Varney
Original Assignee
Neurolixis
Uniwersytet Jagielloński Collegium Medicum
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurolixis, Uniwersytet Jagielloński Collegium Medicum filed Critical Neurolixis
Publication of PL3664787T3 publication Critical patent/PL3664787T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL18740248.2T 2017-07-20 2018-07-20 Zastosowanie selektywnych agonistów receptora serotoninowego 5-HT1A do leczenia skutków ubocznych inhibitorów VMAT PL3664787T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17305969 2017-07-20
PCT/EP2018/069731 WO2019016357A1 (en) 2017-07-20 2018-07-20 USE OF SELECTIVE 5-HT1A SEROTONIN RECEPTOR AGONISTS TO TREAT THE ADVERSE EFFECTS OF VMAT INHIBITORS

Publications (1)

Publication Number Publication Date
PL3664787T3 true PL3664787T3 (pl) 2022-10-24

Family

ID=59569242

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18740248.2T PL3664787T3 (pl) 2017-07-20 2018-07-20 Zastosowanie selektywnych agonistów receptora serotoninowego 5-HT1A do leczenia skutków ubocznych inhibitorów VMAT

Country Status (4)

Country Link
US (1) US11191758B2 (pl)
EP (1) EP3664787B1 (pl)
PL (1) PL3664787T3 (pl)
WO (1) WO2019016357A1 (pl)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2755967B1 (fr) 1996-11-21 1999-01-29 Pf Medicament Derives de la pyridin-2-yl-methylamine, leur procede de preparation et leur application comme medicaments
FR2840900B1 (fr) 2002-06-18 2005-02-25 Pf Medicament Nouveaux derives d'aryl[4-halogeno-4- [(heteroaryl-methylamino)-methyl]-piperidin-1-yl]-methanone, leur procede de preparation et leur utilisation a titre de medicaments
CN104470585A (zh) 2012-04-04 2015-03-25 爱华克斯国际有限公司 用于联合疗法的药物组合物
WO2015171547A1 (en) 2014-05-05 2015-11-12 Ovid Therapeutics Inc. Methods of treating cognitive impairment associated with neurodegenerative disorders
HUE037945T2 (hu) 2014-07-09 2018-09-28 Pf Medicament Eljárás mozgási rendellenességek kezelésére befiradollal

Also Published As

Publication number Publication date
EP3664787B1 (en) 2022-07-20
US20200155535A1 (en) 2020-05-21
WO2019016357A1 (en) 2019-01-24
EP3664787A1 (en) 2020-06-17
US11191758B2 (en) 2021-12-07

Similar Documents

Publication Publication Date Title
EA201992474A2 (ru) Агонисты 5ht для лечения нарушений
IL291000A (en) Benzimidazole derivatives as erbb tyrosine kinase inhibitors for cancer therapy
IL285201A (en) EZH2 inhibitors for the treatment of lymphoma
PH12017501046A1 (en) Azabicyclooctane derivatives as fxr agonists for use in the treatment of liver and gastrointestinal diseases
IL256056A (en) ezh2 inhibitors for the treatment of lymphoma
IL272444A (en) Compounds, their salts and methods for treating diseases
MX2017014192A (es) Composiciones y metodos de tratamiento de una enfermedad neurodegenerativa.
IL261015A (en) History of methylamine as lysis oxidase inhibitors for cancer treatment
IL253979A0 (en) Methods, preparations and kits for cancer treatment
EP3464643A4 (en) USE OF EZH2 INHIBITORS FOR THE TREATMENT OF CANCER
IL268430A (en) Methods for treating cancer using hsp90 inhibitors
MX2017011206A (es) Combinacion de un antagonista con muerte programada 1 (pd-1) y eribulina para el tratamiento de cancer.
TW201713341A (en) Compositions and methods of treating a neurodegenerative disease
EP3195866A4 (en) Pharmaceutical composition for treating flt3 mutation-positive cancer, flt3 mutant inhibitor, and use of said pharmaceutical composition and said inhibitor
IL280158A (en) Methods of treating cancer with the PI3K inhibitor, GDC-0077
EP3131552A4 (en) Methods for treating cancer using tor kinase inhibitor combination therapy
EP3471830A4 (en) EZH2 INHIBITORS TO TREAT CANCER
IL268676A (en) Inhibition of SMARCA2 for cancer therapy
IL274198A (en) Use of Nox inhibitors to treat cancer
IL268163A (en) Methods, compositions, and kits for treatment of cancer
EP3630080A4 (en) USE OF EZH2 INHIBITORS FOR THE TREATMENT OF CANCER
IL283659A (en) Methods for treating cancer resistant to cdk4/6 inhibitors
EP3490554A4 (en) USES OF DOPAMINE BETA HYDROXYLASE (DBH) INHIBITORS AND SEROTONIN (5-HT) RECEPTOR ANTAGONISTS FOR CANCER TREATMENT
PL3664787T3 (pl) Zastosowanie selektywnych agonistów receptora serotoninowego 5-HT1A do leczenia skutków ubocznych inhibitorów VMAT
IL271967A (en) Methods for treating congenital hypersecretion of insulin